Smith MR - Search Results

1

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.

Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C; Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Carroll PR, et al. Among authors: smith mr. Urology. 2002 Sep;60(3 Suppl 1):1-6. doi: 10.1016/s0090-4295(02)01559-5. Urology. 2002. PMID: 12231036 Review. No abstract available.

2

Changes in body composition during androgen deprivation therapy for prostate cancer.

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Smith MR, et al. J Clin Endocrinol Metab. 2002 Feb;87(2):599-603. doi: 10.1210/jcem.87.2.8299. J Clin Endocrinol Metab. 2002. PMID: 11836291 Clinical Trial.

3

A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients.

Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR. Oh WK, et al. Among authors: smith mr. Cancer Invest. 2002;20(2):186-91. doi: 10.1081/cnv-120001145. Cancer Invest. 2002. PMID: 11901538 Clinical Trial.

4

Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.

Smith MR, Kantoff PW. Smith MR, et al. Invest New Drugs. 2002 May;20(2):195-200. doi: 10.1023/a:1015670126203. Invest New Drugs. 2002. PMID: 12099579 Review.

5

Osteoporosis during androgen deprivation therapy for prostate cancer.

Smith MR. Smith MR. Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. Urology. 2002. PMID: 12231056 Review.

6

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.

Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Smith MR, et al. Cancer. 2002 Nov 1;95(9):1864-8. doi: 10.1002/cncr.10844. Cancer. 2002. PMID: 12404279 Free article. Clinical Trial.

7

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Smith MR, et al. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95. J Urol. 2003. PMID: 12771706 Clinical Trial.

8

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Oh WK, et al. Among authors: smith mr. Urology. 2003 Jul;62(1):99-104. doi: 10.1016/s0090-4295(03)00145-6. Urology. 2003. PMID: 12837431 Clinical Trial.

9

Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.

Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Carroll PR, et al. Among authors: smith mr. J Urol. 2003 Dec;170(6 Pt 2):S3-5. doi: 10.1097/01.ju.0000095101.18470.a0. J Urol. 2003. PMID: 14610403 Review. No abstract available.

10

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.

Smith MR. Smith MR. Urology. 2004 Apr;63(4):742-5. doi: 10.1016/j.urology.2003.10.063. Urology. 2004. PMID: 15072892 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,145 results

Search Page